CapsoVision (CV) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
11 Jun, 2026Opening remarks and agenda
Meeting opened by Senior VP, Finance, with introductions of Board and executive team members, including recent appointments since 2024 and 2025.
Agenda included election of directors, ratification of auditors, closing remarks, and Q&A.
Board and executive committee updates
Board members introduced, highlighting new appointments since 2024 and 2025.
Senior VP, Sales, and independent auditor representative present.
Shareholder proposals
Proposal one: Election of directors Joanne Imperial, Michele Harari, and Henry King for terms until 2029.
Proposal two: Ratification of Baker Tilly as independent registered public accounting firm for 2026.
Partial view of Summaries dataset, powered by Quartr API
Latest events from CapsoVision
- GI diagnostics innovator seeks up to $250M in flexible offerings, highlighting growth and pipeline.CV
Registration filing - Q2 2026 revenue up 10% to $3.6M, but net loss widened and going concern risks remain.CV
Q2 2026 - Q1 2026: $2.8M revenue, 48% margin, $7M net loss, $14M raised, ongoing going concern risk.CV
Q1 2026 - Virtual meeting to re-elect directors, ratify auditor, and review governance and compensation.CV
Proxy filing - AI-driven GI diagnostics firm registers 2.87M shares for resale after $14M private placement.CV
Registration filing - AI-powered capsule endoscopy drives growth and innovation in noninvasive GI screening.CV
Corporate presentation - 2025 revenue rose 15% to $13.6M, but net loss increased to $25.3M amid higher R&D and public costs.CV
Q4 2025 - AI-driven capsule endoscopy platform expands into major GI markets, backed by strong financing.CV
The 38th Annual Roth Conference - Offering 5.25M shares at $5.00–$5.50 to fund R&D; strong growth but ongoing losses and regulatory risks.CV
Registration Filing